EUVIMEDEUVIMED entdecken
Crossref

Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer

Jie Wang, Ye-Chen Xia, Bao-Xing Tian, Ju-Tang Li, Heng-Yu Li, Hui Dong, Xiao-Guang Li, Hua Yu, Yu-Yao Zhu, Jun Ma, Ying-Jie Jiang iD, Guang-Zhi Jin iD

Cancer · 2024

DOI: 10.1002/cncr.35176 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Jie Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Foundation of Tongren Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunohistochemistry (IHC) is an essential technique in surgical and clinical pathology for detecting diagnostic, prognostic, and predictive biomarkers for personalized cancer therapy. However, the lack of standardization and reference controls results in poor reproducibility, and a reliable tool for IHC quantification is urgently required. The objective of this study was to describe a novel approach in which H3F3B (histone H3, family 3B) can be used as an internal reference standard to quantify protein expression levels using IHC.

Methods

The authors enrolled 89 patients who had human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC). They used a novel IHC‐based assay to measure protein expression using H3F3B as the internal reference standard. H3F3B was uniformly expressed at the protein level in all tumor regions in cancer tissues. HER2 expression levels were measured with the H‐score using HALO software.

Results

Kaplan–Meier analysis indicated that, among patients who had HER2‐positive BC in The Cancer Genome Atlas data set and the authors' data set, the subgroup with low HER2 expression had a significantly better prognosis than the subgroup with high HER2 expression. Furthermore, the authors observed that HER2 expression levels were precisely evaluated using the proposed method, which can classify patients who are at higher risk of HER2‐positive BC to receive trastuzumab‐based adjuvant therapy. Dual‐color IHC with H3F3B is an excellent tool for internal and external quality control of HER2 expression assays.

Conclusions

The proposed IHC‐based quantification method accurately assesses HER2 expression levels and provides insights for predicting clinical prognosis in patients with HER2‐positive BC who receive trastuzumab‐based adjuvant therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleHistonesImmunohistochemistryReproducibility of ResultsErb-b2 Receptor Tyrosine KinasesTrastuzumabReference StandardsBiomarkers, Tumor

Stichwörter der Autor:innen

HALOhistone 3, family 3 (H3F3B)human epidermal growth factor receptor 2 (HER2)‐positive breast cancerimmunohistochemistryinternal reference marker

Substanzen

HistonesErb-b2 Receptor Tyrosine KinasesTrastuzumabBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Department of Breast Surgery, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Obstetrics and Gynecology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Thyroid and Breast Surgery, Changhai Hospital, Naval Military Medical University, Shanghai, China.
  • Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
  • Department of General Surgery, Shanghai Fourth People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, China.

ORCID-Profile: Ying-Jie Jiang, Guang-Zhi Jin

Förderung

  • National Natural Science Foundation of China
  • Foundation of Tongren Hospital

Zitieren

APA

Wang, J., Xia, Y. C., Tian, B. X., Li, J. T., Li, H. Y., Dong, H., Li, X. G., Yu, H., Zhu, Y. Y., Ma, J., Jiang, Y. J., & Jin, G. Z. (2024). Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer. Cancer. https://doi.org/10.1002/cncr.35176

Vancouver

Wang J, Xia YC, Tian BX, Li JT, Li HY, Dong H, et al. Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer. Cancer. 2024. doi:10.1002/cncr.35176

BibTeX
@article{Wang2024,
  author = {Wang, Jie and Xia, Ye-Chen and Tian, Bao-Xing and Li, Ju-Tang and Li, Heng-Yu and Dong, Hui and Li, Xiao-Guang and Yu, Hua and Zhu, Yu-Yao and Ma, Jun and Jiang, Ying-Jie and Jin, Guang-Zhi},
  title = {Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35176}
}
Kostenlos starten →